Pediatr. praxi. 2011;12(6):398-404

Use of bacterial lysates in clinical practice

doc.MUDr.Jaromír Bystroň, CSc.
Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc

The author presents an overview of the past and present of the clinical use of bacterial lysates. The latest knowledge on the mechanisms

of action of these agents is provided and also discussed are the indications and the most common issues concerning the use of bacterial

lysates in clinical practice.

Keywords: immunity, bacterial lysates, recurrent infections

Published: December 10, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bystroň J. Use of bacterial lysates in clinical practice. Pediatr. praxi. 2011;12(6):398-404.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dunlop JM. The history of immunisation. Public Health 1988; 102: 199-203. Go to original source... Go to PubMed...
    2. Sedláček K. Immunoterapie. Věd. nakladatelství Jaroslav Tožička, Praha, 1937.
    3. Johanovský J. Příprava stafylokokového toxinu a anatoxinu kultivací na celofánu. Čs. epidem. 1956; (5): 41-45.
    4. Malota H, Běhounková L, Maršálek E. Mikrobielle Gesamtantigene in der Behandlung allergisher Zustande und chronischer Entzundungen. Alergie Asthma 1960; 6: 232-242.
    5. Maršálek E, Malota H, Běhounková L. Léčení průduškové záduchy úplnými mikrobiálními antigeny. Čas. lék. čes. 1960; 99: 1514-1519.
    6. Maršálek E, Černá I, Malota H, a kol. Příprava mikrobiálního antigenního komplexu k diagnostice a léčbě infekčně alergických onemocnění. Čs. epid. mikrob. imunol. 1971; 20.
    7. PV4172-89: Nespecifická bakteriální vakcína k prevenci a terapii bakteriálních, houbových a virových infekcí.
    8. Stanek J, et al. Preventive administration of GS Imunostim as a protection against acute respiratory infections. Cent Eur J Publ Health 2006; 14(3): 130-132. Go to original source... Go to PubMed...
    9. Bystroň J, a kol. Účinnost a bezpečnost perorálního bakteriálního imunomodulátoru Olimunovac u pacientů s častými infekcemi dýchacích cest. (Observační multicentrická studie). Alergie, 2011; 13(1): 58-66.
    10. Nimier K, Wolff F, Allouch PY, et al. Protective effects of RU 41740, a bacterial immunomodulator, against experimental infection: induction of cytokine and immunoglobulin release in mice after oral administration. Int J Immunopharmacol 1999; 21(9): 561-574. Go to original source... Go to PubMed...
    11. Saada HN, Azab KS, Zahran AM. Post-radiation effect of Broncho-vaxom, OM-85 BV, and its relationship to anti-oxidant activities. Pharmazie 2001; 56(8): 654-656. Go to PubMed...
    12. Conti-Freitas LC, Foss-Freitas MC, et al. Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer. Cancer Immunol Immunother. 2009; 58: 25-29. Go to original source... Go to PubMed...
    13. Athie-Morales V, O´Connor GM, Gardiner CM. Activation of human NK cells by the bacterial pathogen associated molecular pattern muramyl dipeptide. J Immunol. 2008; 180: 4082-4089. Go to original source... Go to PubMed...
    14. Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment od osteosarcoma. Expert Rev Anticancer Ther. 2009; 9: 1035-1049. Go to original source... Go to PubMed...
    15. Hajdúch M, Weigl E. Vliv imunomodulace Olimunostimem na změny imunologických parametrů experimentálních zvířat alterovaných infekcí nebo nádorem. Imunologický seminář - Regulace imunitní odpovědi. Seč-Ústupky, květen 1992 (sborník str. 38).
    16. Guggenbichler JP. Sborník konference: Slizniční imunita a uplatnění imunomodulace v alergologii, pediatrii, geriatrii a urologii. Praha, Brno, Bratislava květen 2006.
    17. Ferenčík M. Receptory podobné Toll (TLRs), prirodzená imunita a alergický zápal. Alergie 2003; 1: 35-42.
    18. Kalliomaki M, Salminen S, Arvilommi, et al. Probiotics in primary prevention of atopic disease: a randomized placebo controlled trial. Lancet 2001; 375: 1076-1079. Go to original source... Go to PubMed...
    19. Lodinová-Žádníková R. Probiotika v pediatrii: Snížení rizika nosokomiálních infekcí perorálním osídlením probiotickým kmenem E. coli po narození a jeho vliv na frekvenci opakovaných infekcí a alergií po 10 a 20 letech. Alergie 2002; 4: 275-279.
    20. Bowman LM, Holt PG. Selective Enhancement of Systemic Th1 Immunity in Immunologically Immature Rats with an Orally Administered Bacterial Extract. Infection and Immunity, 2001; 6: 3719-3727. Go to original source... Go to PubMed...
    21. Byl B, Libin M, Gerard M, et al. Bacterial extract OM85.BV induces interleukin -12 dependent IFN-gamma production by human CD4+ T cells. Journal of Interferon and Cytokine Research 1998; 18(10): 817-821. Go to original source... Go to PubMed...
    22. Steurer-Stey C, Lagler L, Strub DA, et al. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur. J. Pediatr 2007; 166(4): 365-376. Go to original source... Go to PubMed...
    23. Bystroň J, Heřmanová Z, Szotkovská J, Pazderová D. Investigation of clinical efficacy and influence of ribosomal immunotherapy on plasma levels of cytokines IL-4, IL-5, IL-12, IFN? and total IgE in grass-pollen allergy patients during pollenseason. Allergy 2002; 57(Suppl 73), abstract No 173. Go to PubMed...
    24. Bystroň J, Heřmanová Z, Szotkovská J, Heller L. Comparison of ribosomal immunotherapy on plasmatic levels of total IgE and cytokines IL-4,IL-5,IL-12 and IFN? in atopic and non-atopic adults during grass-pollen season. Allergy 2002; 57(Suppl 73): abstract 176. Go to PubMed...
    25. Bene MC, Faure GC. From Peyer´s patches to tonsills. Specific stimulation with ribosomal immunotherapy. Drugs 1997, 54(Suppl 1): 24-28. Go to original source... Go to PubMed...
    26. HbabiHaddioui L, Roques C. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal. Drugs 1997; 54: 29-32. Go to original source... Go to PubMed...
    27. Lanzilli G, Falcheti R, et al. In vivo effect of an immunostimulating bacterial lysate on human B lymfocytes. Int J Immunopathol Pharmacol. 2006; 19: 551-559. Go to original source... Go to PubMed...
    28. Ha US, CHo YH. Immunostimulation with Escherichia coli extrakt: prevention of recurrent urinary tract infections. International J Antimicrob Agent 2008; 31(Suppl 1): S63-67. Go to original source... Go to PubMed...
    29. Brado F, Tarantini F, Ghiglione V, et al. Bakteria lysate in the prevention of acute exacerbation respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis 2007; 2(3): 335-345. Go to PubMed...
    30. Bystroň J. Kdy a jak používat bakteriální imunomodulátory? Česko-slovenská pediatrie 1997; 52(3): 157-162.
    31. Bystroň J. Bakteriální imunomodulátory v ORL praxi. Otorinolaryng. a Foniat. 2000; (2): 73-81.
    32. Del-Rio-Navarro BE, Espinosa Rosales F, et al. Immunostimulants for preventing respiratory tract infection in children. Cochrane Databaze Syst Rev. 2006: CD004974. Go to original source...
    33. Grevers G, Palacios OA, Rodrigues B, et al. Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open prospective, multinational study. Adv.Ther. 2000; 17(2): 103-116. Go to original source... Go to PubMed...
    34. Berdeaux G, Lafuma A, Peruchet AM, Fagnani F. Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults. Pharmacoeconomics 1998; 14(3): 313-322. Go to original source... Go to PubMed...
    35. Banche G, Allizond V, et al. Improvement of clinical response in allergic rhinitis patiens treated with an oral immunostimulating bacterial lysate: in vivo immunological effects. International J Immunopathol Pharmacol 2007; 20: 129-138. Go to original source... Go to PubMed...
    36. Hyrych KL, Inman RD. Infectious agents in chronic rheumatic diseases. Curr. Opin. Rheumatol. 2001; 13(4): 300-304. Go to original source... Go to PubMed...
    37. Rovenský J, Švík K, Stančíková M, Ištok R. Vplyv imunostimulačného preparátu Ribomunylu na účinok cyklosporínu a metotrexátu při adjuvantnej artritíde u potkanov. Rheumatologia 2003; 17(1): 15-27.
    38. Pérez-García R, Pérez-García A, Verbeelen D, et al: AM3 (Immunoferón) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int. 2002; 61: 1845-1852. Go to original source... Go to PubMed...
    39. Spisek R, Brazova J, Rozkova D, and al. Maturation of dendritic cells by bacterial immunomodulators. Vaccine, 29, 22(21-22): 2761-2768. Go to original source... Go to PubMed...
    40. Carmona-Ramirez MA, Alvarez-Gomez V, Berber A. Use of OM-85 BV for the prevention of acute respiratory tract infection in occupational medicine. Journal of International Medical Research, 2002; 30(3): 325-329. Go to original source... Go to PubMed...
    41. Del-Rio-Navarro BE, Luis Sierra-Monge JJ, Berber A, et al. Use of OM-85 BV in children suffering from recurrent respiratory tract infection and subnormal IgG subclass levels. Allergologia et Immunopathologia 2003; 31(1): 7-13. Go to original source... Go to PubMed...
    42. Gutierrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children duruing 12 months. Chest 2001; 119: 1742-1748. Go to original source... Go to PubMed...
    43. Paupe J. Immunotherapy with an oral bacterial extrakt (OM-85 BV) for upper respiratory infections. Respiration 1991; 58: 150-154. Go to original source... Go to PubMed...
    44. Rutishauser M, Pitzke P, Grevers G, et al. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infection: results of a prospective, placebo-controlled, randomized, double-blind study. Adv. Ther. 1998; 15(6): 330-341.
    45. Schaad UB, Mutterlein R, Goffin H. Immunostimulation with OM-85 in children with recurrent infections of upper respiratory tract: double-blind, placebo-controlled multicenter study. Chest 2002; 122(6): 2042-2049. Go to original source... Go to PubMed...
    46. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. Biodrugs 2003; 17: 355-367. Go to original source... Go to PubMed...
    47. Bousquet J, Fiocchi A. Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review. Pediatr. Drugs 2006; 8(4): 235-243. Go to original source... Go to PubMed...
    48. Clot J. Pharmacology of ribosomal immunotherapy. Drugs 1997; 54(Suppl 1): 33-36. Go to original source... Go to PubMed...
    49. Jara-Pérez JV, Berber A. Primary Prevention of Acute Respiratory Tract Infections in Children Using a Bacterial Immunostimulant: A Double-Masked, Placebo-Controlled Clinical Trial. Clinical Therapeutics 2000; 22(6): 748-759. Go to original source... Go to PubMed...
    50. Mora P, Barbieri M, Passcali GC, et al. A preventive measure for otitis media in children with upper respiratory tract infections. Int. J Pediatr Otorhinolaryngol. 2002; 63(2): 111-118. Go to original source... Go to PubMed...
    51. Mora R, Dellepiane M, Crippa B, Salami A. Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children. Int. J. Pediatr Otorinolaryngol. 2007; 71(2): 257-261. Go to original source... Go to PubMed...
    52. Portales P, Clot J. Immunostimulants revisited: focus on the pharmacology of Ribomunyl. Biodrugs 2006; 20: 81-84. Go to original source... Go to PubMed...
    53. Ruah SB, Ruah C, van Aubel A, et al. Efficacy of polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv.Ther. 2001; 18(4): 151-162. Go to original source... Go to PubMed...
    54. Bauer HW, Alloussi S, et al. Multicenter UTISG. A long-term multicenter, double-blind study of a Escherichia coli extrakt (OM-89) in female patiens with recurrent urinary tract infections. Eur Urol 2005; 47: 542-548. Go to original source... Go to PubMed...
    55. Arandjus C, Blafl PN, Poklepu, et al. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Resp Med 2006; 100(10): 1671-1681. Go to original source... Go to PubMed...
    56. Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Canadian Respir. Journal 2001; 8(1): 27-33. Go to original source... Go to PubMed...
    57. Collet JP, Shapiro S, Ernst P, et al. Effects of an Immunostimulating Agent on Acute Exacerbations and Hospitalizations in patients with Chronic Obstructive Pulmonary Disease. Am J Resp Crit Care Med 1997; 156: 1719-1724. Go to original source... Go to PubMed...
    58. Soler M, Mutterlein R, Vozka G, et al. Double-blind study of OM-85 in patiens with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007: 74: 26-32. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.